This on-demand webcast is available with synchronized slides and video/audio.

To be eligible for credit, participants must complete the educational activity, complete the 4-question post-test with a minimum score of 70%, and complete the activity evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: January 20, 2023
Expiration Date: January 20, 2024
Estimated Time to Complete: 1.75 hour

There is no fee associated with this activity.

After participating in this activity, learners should be better able to:

• Describe testing and 1st – 3rd line treatment options for metastatic NSCLC according to current guidelines with a focus on EGFR and MET alterations
• Evaluate current clinical data concerning the efficacy, safety, and potential sequencing of EGFR and MET-targeted therapies
• Implement strategies to anticipate and address/mitigate the most common and serious adverse events associated with EGFR and MET-targeted therapies in NSCLC